Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

NCT03939637 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03939637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03939637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
Lead sponsor
Baylor College of Medicine
Phase
Phase 3
Overall status
Completed
Start date
May 2, 2019
Completion date
February 26, 2025
Enrollment
122 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia